Michael Rafii, MD, PhD

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation	Abnormalities, Multiple, Alzheimer disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Down syndrome, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, chromosomal disorder, cognitive disorder, dementia, hereditary disease, intellectual disability, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Not yet recruiting	Phase 4	2026-05-15		NCT06911944

Clinical trials